31 results
424B5
PRME
Prime Medicine Inc
16 Feb 24
Prospectus supplement for primary offering
6:17am
portfolio include the following:
PM359, our first product candidate within our hematology and immunology area of focus, targets chronic granulomatous
424B5
PRME
Prime Medicine Inc
14 Feb 24
Prospectus supplement for primary offering
5:27pm
hematology and immunology area of focus, targets chronic granulomatous disease, or CGD, a serious life-threatening disease that presents in childhood. PM359
8-K
EX-99.2
PRME
Prime Medicine Inc
7 Aug 23
Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates
4:04pm
, correct, insert, and delete Performs and corrects insertions, deletions, and all twelve types of single base pair corrections Precisely targets … GGCCCAG-CTGAGCTCGTGA Targeted Sequencing (>1000x) potential off-target editing sites Identified Off-targets Genome wide Nick Detection Assay** Genome
10-Q
0j4k20m3usmfh4u9c70
14 Nov 22
Quarterly report
4:46pm
424B4
m5o2fgf 21bp64p
21 Oct 22
Prospectus supplement with pricing info
4:47pm
S-1/A
l64eej2eq2w nmm3
13 Oct 22
IPO registration (amended)
10:51am
S-1
EX-10.14
h80 9rxd8o235aa
23 Sep 22
IPO registration
4:12pm
S-1
vpj2 kmvhyc3ueh
23 Sep 22
IPO registration
4:12pm
S-1
EX-10.4
3ujcqg1q9799980n1p
23 Sep 22
IPO registration
4:12pm
S-1
EX-10.13
i15bgko
23 Sep 22
IPO registration
4:12pm
DRS/A
jgh1r
5 Aug 22
Draft registration statement (amended)
12:00am
DRS/A
88gse4
6 May 22
Draft registration statement (amended)
12:00am
DRS/A
0fu1jk87rv mc6u7dl
8 Apr 22
Draft registration statement (amended)
12:00am
DRSLTR
fl49t
8 Apr 22
Correspondence regarding draft registration statement
12:00am
UPLOAD
awcdq3ew27t7cb tu
30 Mar 22
Letter from SEC
12:00am
DRSLTR
c2xypz1z8p
25 Mar 22
Correspondence regarding draft registration statement
12:00am
DRS/A
vyz77s
25 Mar 22
Draft registration statement (amended)
12:00am